By taking his inspiration from nature, including the elephant nose fish, insects and arthropods, the University of Wisconsin's Hongrui Jiang is making progress on a 'smart' contact lens that can automatically refocus, to the benefit of those with presbyopia, or the stiffening of the eye, which causes difficulties focusing on nearby objects.
GE Healthcare is rolling out digital pathology software that could help doctors diagnose cancer more quickly. The move comes a few months after GE launched cloud-based radiology apps to give healthcare providers more options for analysis and data storage.
Spirox has attracted a lineup of deep-pocketed VCs in its $45 million Series C round. Private equity firm KKR led the round, with participation from new investor HealthQuest Capital in addition to existing shareholders Aisling Capital, Aperture Venture Partners and Venrock. The Menlo Park, CA-based startup intends to use all that cash to help it develop a novel, minimally invasive treatment for nasal obstruction.
The quest for a better diabetes treatment continues as researchers look for a way to substitute daily injections with a more convenient delivery method. And scientists from the University of North Carolina at Chapel Hill and North Carolina State University have loaded a skin patch with insulin-producing beta cells to safely control blood sugar levels.
Gilead Sciences' move into the cancer business has hit a snag. The company stopped 6 Zydelig trials on Monday after reports of serious side effects--including multiple deaths--among participants in several of the studies.
Eli Lilly, at work on a huge Alzheimer's disease study with implications for the whole drug industry, is changing the main goal of its trial to reflect what the company called "emerging scientific evidence."
Roche is promising up to $1 billion in exchange for as many as 5 targeted cancer therapies from Blueprint Medicines, looking to bolster its own work in immuno-oncology.
Eli Lilly reported strong Phase I results of its BioChaperone Lispro ultrarapid formulation of insulin, which it in-licensed from Lyon, France's Adocia for $50 million upfront and up to $520 million in milestone payments. The candidate is designed to enable injections before, during or after meals due to its fast-acting nature.
Philips is slated to report with a reorganized business structure that better reflects its HealthTech priorities for the first time with its first-quarter earnings due at the end of April. Philips' CEO Frans van Houten said that he's looking for mid- to high-single-digit growth from each of the three new segments: Connected Care & Health Informatics; Diagnosis & Treatment; and Personal Health.
GV, formerly Google Ventures, has led a $21 million Series B round for Cambridge Epigenetix to back its epigenetic sequencing tech. The company expects that its novel TrueMethyl oxidative bisulfite sequencing technology will offer new methods for diagnostics as drug discovery.